ClinicalTrials.gg
CompletedNCT04583735Updated Jul 1, 2024Results posted

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

A Phase 4 interventional study of TEPEZZA and Placebo in Thyroid Eye Disease and Chronic (Inactive) Thyroid Eye Disease, sponsored by Amgen. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing teprotumumab in Graves Ophthalmopathy — 2 open to participants now, 3 under way, 1 of them phase 3. teprotumumab · Graves Ophthalmopathy.

Enrollment
5th of 12
62 · median 56
Started
2021
with 1 other
Phase 4
3 of 12
1 open now
Registered
4th of 12
by date
Lead sponsor
10 of 12
Amgen

Among the 12 studies testing teprotumumab in Graves Ophthalmopathy, this one is the 5th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 4th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

2 of the 12 studies testing teprotumumab in Graves Ophthalmopathy are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teprotumumab

teprotumumab: first FDA approval 2020 (TEPEZZA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing teprotumumab in Graves Ophthalmopathy, or all of them as a file.
02

Study summary

The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled. There will be a treatment period (through Week 24) and a follow up period (where TEPEZZA will not be infused).

Read the detailed description

This is a randomized, double-masked, placebo-controlled, parallel-group, multicenter trial. Participants will be screened for the trial within 4 weeks prior to Baseline (Day 1). Approximately 57 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 2:1 ratio to receive 8 infusions of TEPEZZA or placebo once every 3 weeks.

All participants will enter a 24-week double-masked Treatment Period, during which trial drug will be infused on Day 1 (Baseline) and Weeks 3, 6, 9, 12, 15, 18 and 21 (with a final visit at Week 24 of the 24-week Treatment Period). At the end of the double-masked Treatment Period (Week 24), all patients will be assessed for treatment response. Non-responders may choose to receive 8 infusions of TEPEZZA in an open-label fashion q3W at Weeks 24, 27, 30, 33, 36, 39, 42 and 45.

Study acquired from Horizon in 2024.

03

Conditions studied

  • Thyroid Eye Disease
  • Chronic (Inactive) Thyroid Eye Disease

Keywords

  • Proptosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written .
  2. Male or female at least 18 years old at Screening.
  3. Initial diagnosis of TED ≥2 years but \<10 years prior to Screening. Clinical diagnosis of stable, chronic (inactive) TED, as determined by participant medical records indicating a Clinical Activity Score (CAS) ≤1 in both eyes for at least 1 year prior to Screening or all of the following:

    1. no progression in proptosis for at least 1 year prior to Screening
    2. if participant has history of diplopia due to TED, no progression in diplopia for at least 1 year prior to Screening
    3. no new inflammatory TED symptoms for at least 1 year prior to Screening
  4. CAS ≤1 at the Screening and Baseline Visits.
  5. Proptosis ≥3-mm increase from participant's Baseline (prior to diagnosis of TED), as estimated by treating physician and/or proptosis ≥3 mm above normal for race and gender.
  6. Participants must be euthyroid with the participant's Baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine and free triiodothyronine levels \<50% above or below the normal limits) at Screening. Every effort should be made to correct the mild hypo- or hyperthyroidism promptly and to maintain the euthyroid state for the full duration of the trial.
  7. Does not require immediate surgical ophthalmological intervention and is not planning corrective surgery/irradiation during the course of the trial.
  8. Diabetic participants must have ≤8.0% at Screening.
  9. Participants with a history of inflammatory bowel disease, ulcerative colitis or Crohn's disease must be in clinical remission for at least 3 months, with no history of bowel surgery within 6 months prior to screening and no planned surgery during the trial. Concomitant stable therapies for inflammatory bowel disease without modifications in the 3 months prior to Screening are allowed.
  10. Women of (including those with an onset of menopause \<2 years prior to Screening, non-therapy-induced amenorrhea for \<12 months prior to Screening, or not surgically sterile [absence of ovaries and/or uterus]) must have a negative serum pregnancy test at Screening and negative urine pregnancy tests at all protocol-specified time points (i.e., prior to each dose and throughout participant's participation); participants who are sexually active with a non-vasectomized male partner must agree to use 2 reliable forms of during the trial, 1 of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started at least 1 full cycle prior to Baseline and continue for 180 days after the last dose of trial drug. Highly effective contraceptive methods (failure rate \<1% per year), when used consistently and correctly, include implants, injectables, combination oral contraceptives, some intrauterine devices, sexual abstinence and vasectomized partner.
  11. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Decreased best-corrected visual acuity due to optic neuropathy, defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect or color defect secondary to optic nerve involvement within the last 6 months.
  2. Corneal decompensation unresponsive to medical management in the study eye
  3. Decrease in proptosis of ≥2 mm in the study eye between Screening and Baseline.
  4. Prior orbital irradiation, orbital decompression in the study eye.
  5. Prior strabismus surgery.
  6. or aspartate aminotransferase >3 × the or estimated ≤30 mL/min/1.73 m2 at Screening.
  7. Use of any (IV, oral, steroid eye drops) for the treatment of TED or other conditions within 3 weeks prior to Screening. Steroids cannot be initiated during the trial. Exceptions include topical and inhaled steroids and steroids used to treat infusion reactions.
  8. Any treatment with rituximab (Rituxan® or MabThera®) within 12 months prior to the first infusion of trial drug or tocilizumab (Actemra® or Roactemra®) within 6 months prior to the first infusion of trial drug. Use of any other non-steroid agent within 3 months prior to the first infusion of trial drug.
  9. Any previous treatment with TEPEZZA, including previous enrollment in this trial or participation in a prior teprotumumab trial.
  10. Treatment with any mAb within 3 months prior to Screening.
  11. Identified pre-existing ophthalmic disease that, in the judgment of the Investigator, would preclude trial participation or complicate interpretation of trial results.
  12. Use of an agent for any condition within 60 days or 5 half-lives, whichever is longer, prior to Screening or anticipated use during the course of the trial.
  13. Malignant condition in the past 12 months (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer in situ).
  14. Pregnant or lactating women.
  15. Current drug or alcohol abuse or history of either within the previous 2 years, in the opinion of the Investigator or as reported by the participant.
  16. Known to any of the components of TEPEZZA or prior hypersensitivity reactions to mAbs.
  17. Poorly controlled infection or untreated or positive viral load for or infections.
  18. Any other condition that, in the opinion of the Investigator, would preclude inclusion in the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Other
    TEPEZZA

    Participants received intravenous infusion of 10 milligrams per kilogram (mg/kg) teprotumumab at first infusion and then 20 mg/kg once every 3 weeks (Q3W) for next 7 infusions during the double masked treatment period. Proptosis non-responders who completed the double-masked treatment period had opted to receive 10 mg/kg teprotumumab at first infusion and then 20 mg/kg Q3W for next 7 infusions during open label treatment period.

    Biological: TEPEZZA

  • Placebo comparator
    Placebo

    Participants received teprotumumab matching placebo by intravenous infusion, Q3W for 8 infusions during the double masked treatment period. Proptosis non-responders who completed the double-masked treatment period had opted to receive 10 mg/kg teprotumumab at first infusion and then 20 mg/kg Q3W for next 7 infusions during open label treatment period.

    Drug: Placebo

Interventions

  • BiologicalTEPEZZA

    Intravenous infusion

    Also known as: teprotumumab-trbw, HZN-001

  • DrugPlacebo

    Intravenous infusion

    Also known as: sodium chloride

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Proptosis of Study Eye at Week 24

    Proptosis assessments were performed using a Hertel exophthalmometer. It measures the anterior projection of the eye from the lateral orbital rim to the cornea (proptosis).

    Time frame: Baseline, week 24

07

Results

Posted Apr 26, 2024

Participant flow

Results reported are for double-masked treatment period (24 weeks) based on the primary completion date of 17 Mar 2023. Study consisted of double-masked treatment period (Week 24) and open label treatment period (Week 48).

Double-masked Treatment Period
Participant flow — Double-masked Treatment Period
MilestoneTeprotumumabPlacebo
Started4220
Intent-to-treat populaton4220
Safety analysis population4120
Completed3919
Not completed31
Withdrew: Adverse event01
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject10
Open-label Treatment Period
Participant flow — Open-label Treatment Period
MilestoneTeprotumumabPlacebo
Started1212
Completed1010
Not completed22
Withdrew: Adverse event11
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up01

Outcome measures

PrimaryChange From Baseline in Proptosis of Study Eye at Week 24

Proptosis assessments were performed using a Hertel exophthalmometer. It measures the anterior projection of the eye from the lateral orbital rim to the cornea (proptosis).

Time frame:
Baseline, week 24
Reported as:
Least squares mean · Millimieter (mm)
Change From Baseline in Proptosis of Study Eye at Week 24
Millimieter (mm)TeprotumumabPlacebo
Change From Baseline in Proptosis of Study Eye at Week 24-2.41 ± 0.228-0.92 ± 0.323
Statistical analysis
  • Teprotumumab vs Placebo · MMRM · p = 0.0004 (MMRM analysis with an unstructured variance-covariance matrix including change from Baseline value as dependent variable \& covariates: Baseline value, treatment group, visit, visit-by-treatment \& visit-by-Baseline value interactions.) · Lsmean difference: -1.48 · 95% CI -2.28 to -0.69

Adverse events

Collected over From first dose of study drug until week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teprotumumab0/41 (0%)1/41 (2.4%)33/41 (80.5%)
Placebo0/20 (0%)1/20 (5%)16/20 (80%)
Most frequent serious events
Most frequent serious events
EventTeprotumumabPlacebo
Diabetic ketoacidosisMetabolism and nutrition disorders0/411/20
Conductive deafnessEar and labyrinth disorders1/410/20
Most frequent other events
Showing 10 of 54
Most frequent other events
EventTeprotumumabPlacebo
Muscle spasmsMusculoskeletal and connective tissue disorders17/413/20
FatigueGeneral disorders9/412/20
DiarrhoeaGastrointestinal disorders8/414/20
HeadacheNervous system disorders7/412/20
Infusion related reactionInjury, poisoning and procedural complications2/413/20
COVID-19Infections and infestations6/412/20
Eye painEye disorders5/411/20
Dry skinSkin and subcutaneous tissue disorders5/410/20
Ear discomfortEar and labyrinth disorders2/412/20
TinnitusEar and labyrinth disorders2/412/20

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants to receive study drug.

Age, Continuous
Age, Continuous(years)TeprotumumabPlaceboTotal
Mean48.6 ± 14.3749.0 ± 16.4548.7 ± 14.94
Sex: Female, Male
Sex: Female, Male(Participants)TeprotumumabPlaceboTotal
Female321850
Male10212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TeprotumumabPlaceboTotal
Hispanic or Latino6511
Not Hispanic or Latino361551
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TeprotumumabPlaceboTotal
American Indian or Alaska Native000
Asian718
Native Hawaiian or Other Pacific Islander000
Black or African American10515
White221234
More than one race325
Unknown or Not Reported000
Proptosis for study eye
Proptosis for study eye(Millimeter)TeprotumumabPlaceboTotal
Mean24.60 ± 3.00724.00 ± 2.82424.40 ± 2.939
08

Study locations

12 sites
  • The Private Practice of Raymond Douglas
    Beverly Hills, California 90210, United States
  • Perlman Medical Offices / UCSD
    La Jolla, California 92037, United States
  • MACRO Trials
    Los Angeles, California 90048, United States
  • Univ of Colorado Dept of Ophthalmology
    Aurora, Colorado 80045, United States
  • Bascom Palmer Eye Institute / Univ of Miami
    Miami, Florida 33136, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University
    Saint Louis, Missouri 63108, United States
  • Las Vegas Endocrinology
    Las Vegas, Nevada 89074, United States
  • Endocrinology Specialists & Thyroid Center
    Greenville, South Carolina 29605, United States
  • Hamilton Eye Institute / U Tennessee
    Memphis, Tennessee 38163, United States
  • Neuro-Eye Clinical Trials
    Houston, Texas 77401, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 52336, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Mar 2023, 18 months.

Results were first posted in Apr 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2020
First posted
Oct 12, 2020
StartActual
Sep 2, 2021
Primary completionActual
Mar 17, 2023
CompletionActual
Oct 12, 2023
Results first posted
Apr 26, 2024
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04583735
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 12, 2020
Start date
Sep 2, 2021
Primary completion
Mar 17, 2023
Completion
Oct 12, 2023
Results posted
Apr 26, 2024
Last update
Jul 1, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teprotumumab

Start the discussion